Literature DB >> 19259664

Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack.

Marcin Okroj1, Leticia Corrales, Anna Stokowska, Ruben Pio, Anna M Blom.   

Abstract

The complement system can be specifically targeted to tumor cells due to molecular changes on their surfaces that are recognized by complement directly or via naturally occurring antibodies. However, tumor cells often overexpress membrane-bound complement inhibitors protecting them from complement attack. We have previously shown that non-small cell lung cancer (NSCLC) cells, additionally to membrane-bound inhibitors, produce substantial amounts of soluble regulators such as factor I (FI) and factor H (FH). Since low oxygen concentration is associated with rapidly growing solid tumors, we studied how NSCLC cells protect themselves from complement attack under hypoxic conditions. Unexpectedly, mRNA levels and secretion of both FI and FH were significantly decreased already after 24 h exposure to hypoxia while cell viability measured by XTT assay and annexin V/7-AAD staining was affected only marginally. Furthermore, we observed decrease of mRNA level and loss of membrane-bound complement inhibitor CD46 and increased deposition of early (C3b) and terminal (C9) complement components on hypoxic NSCLC cells. All three complement pathways (classical, lectin and alternative) were employed to deposit C3b on cell surface. Taken together, our results imply that under hypoxic conditions NSCLC give up some of their available defense mechanisms and become more prone to complement attack.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19259664     DOI: 10.1007/s00262-009-0685-8

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  17 in total

Review 1.  Complement control protein factor H: the good, the bad, and the inadequate.

Authors:  Viviana P Ferreira; Michael K Pangburn; Claudio Cortés
Journal:  Mol Immunol       Date:  2010-08       Impact factor: 4.407

Review 2.  The dual role of complement in cancer and its implication in anti-tumor therapy.

Authors:  Ioannis Kourtzelis; Stavros Rafail
Journal:  Ann Transl Med       Date:  2016-07

Review 3.  Drivers and regulators of humoral innate immune responses to infection and cancer.

Authors:  Deepak Kumar; Yeni Romero; Kaitlynn N Schuck; Haley Smalley; Bibek Subedi; Sherry D Fleming
Journal:  Mol Immunol       Date:  2020-03-18       Impact factor: 4.407

Review 4.  The complement system in the airway epithelium: An overlooked host defense mechanism and therapeutic target?

Authors:  Hrishikesh S Kulkarni; M Kathryn Liszewski; Steven L Brody; John P Atkinson
Journal:  J Allergy Clin Immunol       Date:  2018-01-12       Impact factor: 10.793

5.  The alternative complement pathway regulates pathological angiogenesis in the retina.

Authors:  J Harry Sweigard; Ryoji Yanai; Philipp Gaissert; Magali Saint-Geniez; Keiko Kataoka; Aristomenis Thanos; Gregory L Stahl; John D Lambris; Kip M Connor
Journal:  FASEB J       Date:  2014-03-25       Impact factor: 5.191

6.  Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer.

Authors:  Daniel Ajona; María J Pajares; Leticia Corrales; Jose L Perez-Gracia; Jackeline Agorreta; Maria D Lozano; Wenceslao Torre; Pierre P Massion; Juan P de-Torres; Eloisa Jantus-Lewintre; Carlos Camps; Javier J Zulueta; Luis M Montuenga; Ruben Pio
Journal:  J Natl Cancer Inst       Date:  2013-08-12       Impact factor: 13.506

Review 7.  The role of complement in tumor growth.

Authors:  Ruben Pio; Leticia Corrales; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

8.  Hepatitis B virus X protein up-regulates C4b-binding protein α through activating transcription factor Sp1 in protection of hepatoma cells from complement attack.

Authors:  Guoxing Feng; Jiong Li; Minying Zheng; Zhe Yang; Yunxia Liu; Shuqin Zhang; Lihong Ye; Weiying Zhang; Xiaodong Zhang
Journal:  Oncotarget       Date:  2016-05-10

Review 9.  Context-dependent roles of complement in cancer.

Authors:  Lubka T Roumenina; Marie V Daugan; Florent Petitprez; Catherine Sautès-Fridman; Wolf Herman Fridman
Journal:  Nat Rev Cancer       Date:  2019-10-30       Impact factor: 60.716

Review 10.  Complement inhibition in cancer therapy.

Authors:  Ruben Pio; Daniel Ajona; John D Lambris
Journal:  Semin Immunol       Date:  2013-05-24       Impact factor: 10.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.